<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Recommendations for the treatment of aPL-positive patients with pregnancy morbidity are based on a limited number of well-designed clinical trials </plain></SENT>
<SENT sid="1" pm="."><plain>However, the management of pregnant aPL-positive women still displays several open questions </plain></SENT>
<SENT sid="2" pm="."><plain>OBJECTIVE: To determine the practice patterns of experienced physicians in the management of the controversial aspects of aPL pregnancies </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: A questionnaire reproducing debated conditions was initially sent to the Advisory Board members (ABMs) of the 12th Congress of aPL and the Fifth Conference on Sex Hormones, Pregnancy and <z:e sem="disease" ids="C0035435" disease_type="Disease or Syndrome" abbrv="">Rheumatic Diseases</z:e> (Florence, Italy, April 2007), and then the same questionnaire was posted at the Hospital for Special Surgery (www.hss.edu) website and <z:hpo ids='HP_0000001'>all</z:hpo> attendees (ATS) of the above meetings were invited to participate via e-mail </plain></SENT>
<SENT sid="4" pm="."><plain>Answers have been collected and analysed in a descriptive fashion and responses of the two groups evaluated by Chi-square or Fisher's exact test </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: As a whole 75 responses from the ABMs and ATS were included in the analysis </plain></SENT>
<SENT sid="6" pm="."><plain>In general, there was no significant difference between the opinions of two groups </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: Management recommendations displayed reasonable consistence: (i) for the use of low-dose aspirin and low-molecular weight <z:chebi fb="5" ids="28304">heparin</z:chebi> during pregnancy and during ovarian stimulation for in vitro fertilization; (ii) against <z:chebi fb="67" ids="50114">oestrogen</z:chebi>-containing oral contraceptives; and (iii) for the use of <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> in the post-partum period </plain></SENT>
</text></document>